Toripalimab plus CAV/IE for advanced soft-tissue bone cancers
Part of Cancer clinical trials.
This Phase 2 study tests toripalimab (an immune therapy) combined with CAV/IE chemotherapy for certain advanced or non-surgically removable sarcomas. It may help shrink tumors and slow disease when standard treatments have failed or don’t exist.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) choose to join and sign informed consent.
- Your cancer is a confirmed sarcoma (bone or soft tissue) that is advanced and cannot be removed by surgery, and standard treatment has failed—or there isn’t a standard option.
- Your scans show at least one measurable tumor spot, and MRI or CT can measure it; you must have enough survival time (more than 3 months).
- Your body function tests are strong enough: blood counts, liver, kidneys, and heart pumping (left heart ejection fraction at least 50%).
- You have not previously taken an anti–PD-1 or anti–PD-L1 antibody medicine.
- You cannot have certain other cancers or major health problems that would make treatment unsafe (for example, uncontrolled infection or serious autoimmune disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.